Pharmacotherapy in patients with HF
Are there differences in pharmacotherapy for patients with heart failure depending on their age (advanced vs very advanced)? Which potential adverse effects of drugs should be kept in mind in those groups?
Are there differences in pharmacotherapy for patients with heart failure depending on their age (advanced vs very advanced)? Which potential adverse effects of drugs should be kept in mind in those groups?
Which diagnostic testing should be performed in patients with suspected heart failure with preserved ejection fraction (HFpEF)?
When should we suspect and how to confirm heart failure with preserved ejection fraction (HFpEF) (as the diagnosis may be difficult)?
Dr Reinhold Kreutz from Charité - Universitätsmedizin Berlin, Germany, presents the 3 most important recent advances in the treatment of arterial hypertension.
Dr Tatjana Potpara from the University of Belgrade, Serbia, shares her views on the 3 most important recent advances in treating cardiac arrhythmias.
Dr Harriette Van Spall, associate professor in the Division of Cardiology at McMaster University, shares her views on the 3 most important recent advances in treating heart failure.
Are there still any unknown areas concerning target blood pressure (BP) values and therapeutic goals in older patients with hypertension?
What should be taken into consideration when choosing or switching antiplatelet agents in patients with coronary artery disease (CAD)?
Do you have any suggestions or recommendations on diagnostic workup of peripheral artery disease (PAD) performed by a general practitioner or another nonvascular specialist?
Should aggressive medical treatment be used in every patient with peripheral artery disease (PAD), or should it be adjusted to disease severity?